Found 19 matching trials
Characterization of the Inhibitory Effects of Fevipiprant (QAW039) on Activation of Eosinophils and ILC2 Cells by Prostaglandin D2 Metabolites
NAThe aim of this study is to draw blood from patients with well-defined atop...
Location
Fraunhofer ITEM im CRC
A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia
PHASE2This was an exploratory, randomized, subject- and investigator-blind, place...
Location
Novartis Investigative Site
Study of Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
PHASE3A randomized, multicenter, double-blind, placebo- controlled parallel-group...
Location
Novartis Investigative Site
Efficacy and Safety Study of QAW039 in the Treatment of Patients With Moderate to Severe Atopic Dermatitis.
PHASE2The purpose of this study is to determine whether QAW039 is safe and has be...
Location
Novartis Investigative Site
Efficacy, Safety, and Pharmacokinetics of QAW039
PHASE2This study will assess the safety, efficacy and pharmacokinetics of QAW039 ...
Location
Novartis Investigative Site
Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects
PHASE1This study will characterize the pharmacokinetics (PK) of QAW039 after a si...
Location
Novartis Investigative Site
Systemic Corticosteroids Avoidance Study in Severe Asthma Patients
PHASE3The overall purpose of this study was to determine the efficacy of fevipipr...
Location
Novartis Investigative Site
Safety and Efficacy of QAW039 in Sputum Eosinophilia and Persistent Asthma
PHASE2This study will assess the safety and efficacy of QAW039 when added to curr...
Location
Novartis Investigative Site
Dose Finding Study for QAW039 in Asthma
PHASE2This study aims to demonstrate a clinically significant improvement in Forc...
Location
Novartis Investigative Site
Study of Efficacy of Fevipiprant in Patients With Nasal Polyposis and Asthma
PHASE3A Phase 3b Proof-of-Concept study to evaluate the ability of fevipiprant 15...
Location
Novartis Investigative Site